Prognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with nonmetastatic breast cancer

Carcinogenesis

Volumn 36, Issue 2, 2014, Pages 243-248

  Liu, Xiaoan ^a,b   Meng, Qing H ^a   Ye, Yuanqing ^a   Hildebrandt, Michelle A T ^a   Gu, Jian ^a   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ESTROGEN RECEPTOR; LACTATE DEHYDROGENASE; PROGESTERONE RECEPTOR; PLASMA PROTEIN; SERUM ALBUMIN;

ADULT; AGE; AGED; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BREAST CANCER; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CAUCASIAN; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING; BLOOD; BREAST TUMOR; MIDDLE AGED; MORTALITY; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; BLOOD PROTEINS; BREAST NEOPLASMS; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; LIVER FUNCTION TESTS; MIDDLE AGED; PROGNOSIS; SERUM ALBUMIN; YOUNG ADULT;

EID: 84928198361     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu247     Document Type: Article

References (33)

1. Early Breast Cancer Trialists' Collaborative Group. (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet, 339, 1-15.
2. D'Eredita', G. et al. (2001) Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution. Eur. J. Cancer, 37, 591-596.
3. Ravdin, P.M. et al. (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J. Clin. Oncol., 19, 980-991.
4. Dawood, S. et al. (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutionalbased review. J. Clin. Oncol., 28, 92-98.
5. Paik, S. et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med., 351, 2817-2826.
6. Parker, J.S. et al. (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol., 27, 1160-1167.
7. Dowsett, M. et al. (2013) Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J. Clin. Oncol., 31, 2783-2790.
8. Gupta, D. et al. (2010) Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr. J., 9, 69.
9. Liu, Z. et al. (2014) Complex association between alanine aminotransferase activity and mortality in general population: a systematic review and meta-analysis of prospective studies. PLoS One, 9, e91410.
10. Brown, J.E. et al. (2012) Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients. Clin. Cancer Res., 18, 6348-6355.
11. Wyld, L. et al. (2003) Prognostic factors for patients with hepatic metastases from breast cancer. Br. J. Cancer, 89, 284-290.
12. Heys, S.D. et al. (1998) Acute phase proteins in patients with large and locally advanced breast cancer treated with neo-adjuvant chemotherapy: response and survival. Int. J. Oncol., 13, 589-594.
13. Lis, C.G. et al. (2003) Is serum albumin an independent predictor of survival in patients with breast cancer? JPEN. J. Parenter. Enteral Nutr., 27, 10-15.
14. O'Brien, S.M. (2004) Cutpoint selection for categorizing a continuous predictor. Biometrics, 60, 504-509.
15. Yeun, J.Y. et al. (1998) Factors influencing serum albumin in dialysis patients. Am. J. Kidney Dis., 32 (6 suppl. 4), S118-S125.
16. Hébuterne, X. et al. (2014) Prevalence of malnutrition and current use of nutrition support in patients with cancer. JPEN. J. Parenter. Enteral Nutr., 38, 196-204.
17. Pressoir, M. et al. (2010) Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres. Br. J. Cancer, 102, 966-971.
18. Wie, G.A. et al. (2010) Prevalence and risk factors of malnutrition among cancer patients according to tumor location and stage in the National Cancer Center in Korea. Nutrition, 26, 263-268.
19. Boonpipattanapong, T. et al. (2006) Preoperative carcinoembryonic antigen and albumin in predicting survival in patients with colon and rectal carcinomas. J. Clin. Gastroenterol., 40, 592-595.
20. Neal, C.P. et al. (2009) Evaluation of the prognostic value of systemic inflammation and socioeconomic deprivation in patients with resectable colorectal liver metastases. Eur. J. Cancer, 45, 56-64.
21. Win, T. et al. (2008) Predicting survival in potentially curable lung cancer patients. Lung, 186, 97-102.
22. Sharma, R. et al. (2008) Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer. Eur. J. Cancer, 44, 251-256.
23. Sagman, U. et al. (1991) The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer. J. Clin. Oncol., 9, 954-961.
24. Faloppi, L. et al. (2014) The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management. BMC Cancer, 14, 110.
25. Kolev, Y. et al. (2008) Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer: association with hypoxia-inducible factor (HIF-1alpha) pathway, angiogenic factors production and poor prognosis. Ann. Surg. Oncol., 15, 2336-2344.
26. Koukourakis, M.I. et al. (2011) Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy. Clin. Cancer Res., 17, 4892-4900.
27. Scartozzi, M. et al. (2012) Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. Br. J. Cancer, 106, 799-804.
28. Yamamoto, N. et al. (1998) Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J. Clin. Oncol., 16, 2401-2408.
29. Horsfall, L.J. et al. (2011) Serum bilirubin and risk of respiratory disease and death. JAMA, 305, 691-697.
30. Novotný, L. et al. (2003) Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp. Biol. Med. (Maywood)., 228, 568-571.
31. Alexandre, J. et al. (2000) Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J. Clin. Oncol., 18, 562-573.
32. Ravishankaran, P. et al. (2011) Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. World J. Surg. Oncol., 9, 18.
33. Tomita, M. et al. (2014) Prognostic significance of pre- and postoperative glasgow prognostic score for patients with non-small cell lung cancer. Anticancer Res., 34, 3137-3140.